Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Digma Medical
Giv'at Shmuel, Israeldigmamedical.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Digma Medical is developing a minimally invasive, endoscopic device-based procedure called Endoscopic Glycemic Management (EGM) using its DiaGone system. The approach targets the duodenum to restore glycemic control in type 2 diabetes patients. Clinical trials, including a completed Phase 3 sham-controlled study and first-in-human studies, have shown initial positive safety and efficacy results for long-term remission of type 2 diabetes[3][4].
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- DeviceNon-pharmacological therapy (endoscopic laser ablation)
- Industry
- Therapeutic Medical Devices
02
Partnerships
MedTech Innovator accelerator cohort
Beyond the preview
Go deeper on Digma Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Digma Medical.